v3.25.2
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 9 – Segment Reporting

 

The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, currently located in a single geographic location, the United States. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. Since the Company operates in a single segment, the measure of segment total assets and loss from operations is the same as that reported on the accompanying balance sheets as total assets, and the accompanying statement of operations as loss from operations, respective.

 

The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The Company’s CODM reviews and evaluates the total consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. In addition to the significant expense categories included within the total net loss presented on the Company’s Statements of Operations, the following table sets forth significant segment expenses:

 

   2025   2024 
   March 31, 
   2025   2024 
Patient revenue, net  $1,500   $- 
Cost of revenues   103,187    - 
Gross profit (loss)   (101,687)   - 
           
Operating expenses          
Employee expense   802,041    150,202 
Professional fees   1,063,205    157,736 
Occupancy   65,986    2,077 
Insurance   70,506    81,840 
Other   85,475    16,775 
Total operating expenses   2,087,213    408,630 
           
Operating loss   (2,188,900)   (408,630)
           
Interest income   185    204 
Interest expense   (11,466)   (40,473)
Total other income (expenses)   (11,281)   (40,269)
           
Income (loss) from continuing operations, net of income taxes  $(2,200,181)  $(448,899)